Toxina botulínica no tratamento da dor
Botulinum toxin in pain treatment
Orlando Carlos Gomes Colhado; Marcelo Boeing; Luciano Bornia Ortega
Resumo
Palavras-chave
Abstract
Keywords
References
Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005;63:180-185.
Lang A. History and uses of BOTOX (botulinum toxin type A). Lippincott's Case Manag. 2004;9:109-112.
Wenzel RG. Pharmacology of botulinum neurotoxin serotype A. Am J Heath-Syst Pharm. 2004;61(^s6):s5-10.
Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002;18(^s6):s119-124.
Aguilar-Rebolledo F, Hernandez-Sanchez J, Rayo-Mares D. Toxina botulínica como tratamiento de la espasticidad y distonia en la parálisis cerebral infantil. Gac Méd Mex. 2001;137:403-411.
Wohlfarth K, Kampe K, Bigalke H. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov Disord. 2004;19:s65-67.
Unno Ek, Sakato RK, Issy AM. Estudo comparativo entre toxina botulínica e bupivacaína para infiltração de pontos-gatilho em síndrome dolorosa miofascial crônica. Rev Bras Anestesiol. 2005;55:250-255.
Purves D, Augustine GJ, Fitzpatrick D. Neuroscience. 2004:110-116.
Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785-793.
Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain. 2003;4:159-165.
Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248(^s1):3-10.
Dressler D, Chaná Cuevas P. La toxina botulínica tipo B: Dónde estamos?. Rev Chil Neuro-psiquiatr. 2002;40:6-8.
Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord. 2005;20:592-597.
Cardoso F. Toxina botulínica tipo B no manejo de distonia não-responsiva à toxina botulínica tipo A. Arq Neuropsiquiatr. 2003;61:607-610.
Yablon S. Toxin neutralizing antibody formation with botulinum toxin type A (BoNTA) treatment in neuromuscular disorders. Neurology. 2005;64:1153.
Comella CL. Interim results of an observation study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia. Neurology. 2004;62:6141.
Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study. Pain. 2005;118:170-175.
Sycha T, Samal D, Chizh B. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg. 2006;102:509-516.
Sheeran G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep. 2002;6:460-469.
Göbel H, Heinze A, Heinze-Kuhn K. Botulinun toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001;91:195-199.
Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain. 2002;18(^s6):s142-146.
Porta M. A comparative trial of botulinum toxin type A and methilprednisolone for the treatment of myofascial pain syndrome and pain for chronic muscle spasm. Pain. 2000;85:101-105.
Klein AW. The therapeutic potential of botulinum toxin. Dermatol Surg. 2004;30:452-455.
Porta M, Perreti A, Gamba M. The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A. Pain Digest. 1998;8:346-352.
Kamanli A, Kaya A, Ardicoglu O. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int. 2005;25:604-611.
von Lindern JJ, Niederhagen B, Bergé S. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61:774-778.
Jabbari B, Ney J, Sichani A. Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study. Pain Med. 2006;7:260-264.
Gassner HG, Sherris DA. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study. Mayo Clin Proc. 2000;75:701-704.
Silberstein SD, Gobel H, Jensen R. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006;26:790-800.
Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache. 2004;44:801-805.
Allen G, Galer BS, Schwartz L. Epidemiology of complex regional pain syndrome: a retrospective chart review of 134 patients. Pain. 1999;80:539-544.
Argoff CE. Botulinum toxin type A treatment of myofascial pain with CRPS type I (reflex sympathetic dystrophy): a pilot study. . .
Jabbari B, Maher N. Effectiveness of botulinum toxin A against the segmental burning pain of spinal cord origin. . .
Lang AM. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil. 2003;84(3^s1):s69-73.